Abstract
This article considers merits and drawbacks of “undetectable = untransmissible” (U = U) messaging in the global HIV response. First, viral suppression might be achieved with effective treatment, but not everyone living with HIV has access to such intervention and care. Second, although U = U can help individuals living with HIV, this messaging might stigmatize those for whom interventions have not achieved viral suppression. Third, although biomedical advances have attempted to address infectiousness, syndemic drivers that predispose individuals to HIV acquisition are not well accounted for by U = U messaging.

To claim one AMA PRA Category 1 Credit™ for the CME activity associated with this article, you must do the following: (1) read this article in its entirety, (2) answer at least 80 percent of the quiz questions correctly, and (3) complete an evaluation. The quiz, evaluation, and form for claiming AMA PRA Category 1 Credit™ are available through the AMA Ed Hub™.

Treatment Innovation and U = U Messaging
Since the first case of HIV was reported in 1981, more than 75 million people have been infected with HIV, and more than 32 million have died from AIDS-related illnesses.¹ Since then, life expectancies of people living with HIV have improved.² Biomedical advances produced highly active antiretroviral therapy (HAART) in 1996,³ and, as of August 2020, more than 30 ART medications across 6 classes were available to people living with HIV.⁴ Prospective cohort studies after 1996 demonstrated that individuals with low viral loads only infrequently transmit HIV to HIV-negative partners.⁵,⁶,⁷ This finding led, in 2008, to the “Swiss Statement”: individuals on fully suppressive HAART for at least 6 months who have no sexually transmitted infections cannot transmit HIV through sexual contact.⁸ While many remained unconvinced, more recent evidence from several large-scale, observational cohorts and trials in HIV prevention—including HPTN 052, PARTNER, and Opposites Attract—suggests that HIV transmission risk from an individual with an undetectable viral load to an HIV-negative sexual partner is effectively zero.⁹,¹⁰,¹¹ These studies have motivated global support for “undetectable = untransmissible” (U = U)¹² messaging to reduce stigma and encourage individuals with HIV to start treatment as early as possible. But the merits of U = U messaging must be considered in light of what we should be cautious about; this is the purpose of this article.
Merits
Awareness and implementation of U = U messaging campaigns are gaining global traction, including among physicians and their patients, and has benefited individuals living with HIV and HIV prevention efforts. U = U messaging, for example, has led to new evidence-based guidelines from the Centers for Disease Control and Prevention that endorse condomless intercourse among serodiscordant couples planning to conceive, so these couples no longer require infertility clinic referral for in vitro fertilization, which is costly and, for many, inaccessible. Furthermore, gay, bisexual, and other men who have sex with men (GBMSM) living with HIV who are aware of U = U messaging view having an undetectable viral load as an achievement, as a symbol of having attained optimum health, as a sign of personal and social responsibility to their communities, and as a means of having sexual and romantic partnerships. “Becoming undetectable” allows GBMSM to feel more comfortable having sex and disclosing their HIV status to their sexual partners. For GBMSM, living with an undetectable HIV viral load also means having control over their HIV status and having autonomy in their health and relationship decisions, experiencing a sense of normalcy in their lives, and knowing that their risk of transmitting HIV is, at a population level, dramatically reduced.

Cautions
Yet uncritical advocacy of U = U messaging is unwise without close scrutiny from ethics and public health standpoints of how the messaging is promulgated and received.

Achievement? First, we must be cautious about accepting that U = U messaging is domestically and globally inclusive and closely attentive to structural and psychosocial barriers faced by many to quality care and treatment. Undetectable viral load might be achievable for most, but people living with HIV who have unreliable or irregular access to testing or medication could feel left behind or demoralized by U = U messaging. People in resource-poor settings might lack facilities in which viral load testing can be properly conducted, which problematizes the view that U = U should be, clinically or ethically, regarded as an achievement. Because marginalized people living with HIV, including racial and ethnic minorities and sex workers, experience poverty, discrimination, and other barriers to care, seeing their or anyone’s failures to adhere to HAART regimens and “achieve” undetectability is as stigmatizing as it is expressive of one’s incomplete understanding of HIV care’s complexity. Social determinants and cultural or material conditions that undermine adherence must be carefully considered in U = U messaging, since poor adherence can contribute to evolution of drug-resistant mutations of HIV and since virologic failure and HIV drug resistance have emerged in many low-to-middle-income countries (LMICs). Frequent medication stockouts, economic and political displacement, and other barriers in LMICs suggest how considering viral load suppression as an achievement is unjust and unhelpful.

Othering. Second, U = U messaging can empower some individuals who are living with HIV but inadvertently stigmatize and otherize those for whom HAART intervention has not yet achieved viral suppression. If U = U messaging misfires to deepen divides between HIV-negative and HIV-positive individuals or is interpreted as a means of parsing infectious people with HIV from those who have achieved undetectability and uninfectedness, then U = U messaging will likely have undermined hard-won advances in HIV care, undermined solidarity by designating normal and deviant ways of being a person with HIV, and undermined unity to confer privilege to some and disadvantage to others. Communities inequitably affected by HIV, such as GBMSM,
might develop identities along serological lines, identifying as “undetectable” rather than as “HIV positive” or as being on ART.\(^{28}\) Otherization is a product of stigmatization, and it could result in HAART hesitancy, which would help no one.

**Biomedicalization.** Third, \(U = U\) messaging uses viral load as a biomarker in a social, cultural, and public health change campaign. We must take care that a physiological indicator does not overly biomedicalize HIV, which could muddle how we respond to needs and vulnerabilities of people experiencing the syndemic of HIV, gender inequality, and comorbidity, such as substance use disorder.\(^{29,30}\) Treatment-as-prevention is a key part of \(U = U\) messaging, but it risks oversimplification of how deeply individual biographies and life histories are affected by psychosocial and environmental factors that undermine health equity.\(^{31,32}\) Messaging strategies must be sufficiently designed to resist oversimplification, or at least not to invite it, and to express respect for the plurality of factors that need attention in a good HIV response.

**Message Translation**

\(U = U\) messaging looks to translate game-changing breakthroughs in science to attract the attention of people living with HIV who could benefit from HAART interventions, and it should continue.\(^{33}\) The cautions we’ve suggested here should help us deploy this messaging responsibly and equitably and with great attention not only to what the message is but also how it’s interpreted and received. Messaging should express commitment to equitable access to HIV testing and medication—especially in LMICs—and should help identify and respond robustly to factors that obstruct HIV prevention.

**References**

1. Global HIV and AIDS statistics—2020 fact sheet. UNAIDS. Accessed March 10, 2021. [https://www.unaids.org/en/resources/fact-sheet](https://www.unaids.org/en/resources/fact-sheet)
2. Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. *Curr Opin HIV AIDS*. 2016;11(5):492-500.
3. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. *Cold Spring Harb Perspect Med*. 2012;2(4):a007161.
4. Jones A. Types of antiretroviral medications. Nam Aidsmap. 2020. Accessed December 15, 2020. [http://www.aidsmap.com/about-hiv/types-antiretroviral-medications](http://www.aidsmap.com/about-hiv/types-antiretroviral-medications)
5. Quinn TC, Wawer MJ, Sewankambo N, et al; Rakai Project Study Group. Viral load and heterosexual transmission of human immunodeficiency virus type 1. *N Engl J Med*. 2000;342(13):921-929.
6. Castilla J, Del Romero J, Hernando V, Marincovich B, García S, Rodríguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. *J Acquir Immune Defic Syndr*. 2005;40(1):96-101.
7. Melo MG, Santos BR, De Cassia Lira R, et al. Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, southern Brazil. *Sex Transm Dis*. 2008;35(11):912-915.
8. Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes séropositives ne souffrant d’aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle. *Bull Med Suisses*. 2008;89(5):165-169.
9. Cohen MS, Chen YQ, McCauley M, et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011;365(6):493-505.
10. Rodger AJ, Cambiano V, Bruun T, et al; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171-181.

11. Bavinton BR, Pinto AN, Phanuphak N, et al; Opposites Attract Study Group. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438-e447.

12. Prevention Access Campaign. Risk of sexual transmission of HIV from a person living with HIV who has an undetectable viral load: messaging primer and consensus statement. July 21, 2016. Accessed July 27, 2020. https://www.preventionaccess.org/consensus

13. The Lancet HIV. U=U taking off in 2017. Lancet HIV. 2017;4(11):e475.

14. Gupta N, Gilleece Y, Orkin C. Implementing U=U in clinical practice: results of a British HIV association members survey. Sex Transm Infect. Published online March 5, 2020.

15. Bhatt SJ, Douglas N. Undetectable equals untransmittable (U = U): implications for preconception counseling for human immunodeficiency virus serodiscordant couples. Am J Obstet Gynecol. 2020;222(1):53.e1-53.e4.

16. Tan RKJ, Lim JM, Chan JKW. “Not a walking piece of meat with disease”: meanings of becoming undetectable among HIV-positive gay, bisexual and other men who have sex with men in the U = U era. AIDS Care. 2019;32(3):325-329.

17. Grace D, Chown SA, Kwag M, Steinberg M, Lim E, Gilbert M. Becoming “undetectable”: longitudinal narratives of gay men’s sex lives after a recent HIV diagnosis. AIDS Educ Prev. 2015;27(4):333-349.

18. Roberts T, Cohn J, Bonner K, Hargreaves S. Scale-up of routine viral load testing in resource-poor settings: current and future implementation challenges. Clin Infect Dis. 2016;62(8):1043-1048.

19. Gaston GB, Alleyne-Green B. The impact of African Americans’ beliefs about HIV medical care on treatment adherence: a systematic review and recommendations for interventions. AIDS Behav. 2013;17(1):31-40.

20. Goldenberg SM, Montaner J, Duff P, et al. Structural barriers to antiretroviral therapy among sex workers living with HIV: findings of a longitudinal study in Vancouver, Canada. AIDS Behav. 2016;20(5):977-986.

21. Günthard HF, Calvez V, Paredes R, et al. Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society-USA Panel. Clin Infect Dis. 2019;68(2):177-187.

22. Hwang B, Shroufi A, Gils T, et al. Stock-outs of antiretroviral and tuberculosis medicines in South Africa: a national cross-sectional survey. PLoS One. 2019;14(3):e0212405.

23. Pennings PS. HIV drug resistance: problems and perspectives. Infect Dis Rep. 2013;5(suppl 1):e5.

24. Shao Y, Williamson C. The HIV-1 epidemic: low- to middle-income countries. Cold Spring Harb Perspect Med. 2012;2(3):a007187.

25. Courtenay-Quirk C, Wolitski RJ, Parsons JT, Gómez CA; Seropositive Urban Men’s Study Team. Is HIV/AIDS stigma dividing the gay community? Perceptions of HIV-positive men who have sex with men. AIDS Educ Prev. 2006;18(1):56-67.

26. Halperin DM. Saint Foucault: Towards a Gay Hagiography. Oxford University Press; 1995.

27. Cohen CJ. Punks, bulldaggers, and welfare queens: the radical potential of queer politics? GLQ. 1997;3(4):437-465.
28. Girard G, Patten S, LeBlanc MA, Adam BD, Jackson E. Is HIV prevention creating new biosocialities among gay men? Treatment as prevention and pre-exposure prophylaxis in Canada. *Sociol Health Illn*. 2019;41(3):484-501.

29. Richardson ET, Collins SE, Kung T, et al. Gender inequality and HIV transmission: a global analysis. *J Int AIDS Soc*. 2014;17(1):19035.

30. Lyons CE, Schwartz SR, Murray SM, et al. The role of sex work laws and stigmas in increasing HIV risks among sex workers. *Nat Commun*. 2020;11(1):773.

31. Persson A. Non/infectious corporealities: tensions in the biomedical era of “HIV normalisation.” *Sociol Health Illn*. 2013;35(7):1065-1079.

32. Gaspar M, Marshall Z, Rodrigues R, et al. A tale of two epidemics: gay men’s mental health and the biomedicalisation of HIV prevention and care in Toronto. *Sociol Health Illn*. 2019;41(6):1056-1070.

33. Grace D, Nath R, Parry R, Connell J, Wong J, Grennan T. “...if U equals U what does the second U mean?”: sexual minority men’s accounts of HIV undetectability and intransmittable scepticism. *Cult Health Sex*. 2020:1-17.

Rayner Kay Jin Tan is a postdoctoral fellow at the National University of Singapore’s Saw Swee Hock School of Public Health who anticipates receiving his PhD degree in spring 2021. He has a background in sociology and is a sociobehavioral researcher in public health. His research interests include sexualized substance use, deviance, and social determinants of sexually transmitted infections.

Jane Mingjie Lim, MSW is a PhD candidate at the National University of Singapore’s Saw Swee Hock School of Public Health. Previously, she completed a master of social work degree at the University of Michigan. Her research interests include the drivers of antimicrobial resistance across sectors and the roles that social networks play in the dissemination of health information.

Jeremiah Kah Wai Chan, MSc completed his MSc in medical anthropology at Durham University and his BA in sociology at the National University of Singapore. His research interests include the stigmatization of illnesses such as HIV and the illness narratives crafted by patients experiencing chronic illnesses that impede their progress towards better health outcomes.

Citation
*AMA J Ethics*. 2021;23(5):E418-422.

DOI
10.1001/amajethics.2021.418.

Conflict of Interest Disclosure
The author(s) had no conflicts of interest to disclose.

*The viewpoints expressed in this article are those of the author(s) and do not necessarily reflect the views and policies of the AMA.*

Copyright 2021 American Medical Association. All rights reserved.
ISSN 2376-6980